Abstract: An antibacterial melamine product includes a main body that is formed by heating and filling molding to have a predetermined shape. The main body includes a substrate portion and an antibacterial agent mixed with the substrate portion. The substrate portion is made of melamine formaldehyde. The antibacterial agent is fused in the substrate portion evenly. Thus, the antibacterial agent is mixed with the substrate portion to form the main body so that the main body of the antibacterial melamine product has different antibacterial effects by the antibacterial features provided by the antibacterial agent.

Abstract: Three types of trisiloxane surfactants having the basic formula: MDM? are described wherein the substituents on the differing M and M? groups, in conjunction with pendant polyalkylene oxide substituents on the D group render the surfactant resistant to hydrolysis under either basic or acidic conditions outside the pH range of 6.0 to 7.5. The compositions are useful in agricultural, household and cosmetic applications.

Abstract: A formulation comprising large quantities of l-arginine and/or fat plaque dissolving agents which is palatable, stench free, and does not evoke nausea. The formulation is adapted to facilitate the adsorption of l-arginine to the blood system and to introduce high levels of l-arginine and/or other fat plaque dissolving agents such as EDTA, its derivatives or its salts into the blood system which are sufficient for effectively dissolving fat plaques in the artery. The formulation comprises at least 10% (w/w) L-arginine, edible organic acids, emulsifier(s), preservatives, flavorings, ethanol and water.

Abstract: Methods and compositions for treating wounds, decubitus ulcers, diaper rash, burns, abrasions, and other irritations and relevant injuries are provided. The invention contemplates in one embodiment the use of an aqueous or emollient medium having one or more pH raising ingredients in a composition specifically designed to deliver oxygen to the skin's surface.

Abstract: The present disclosure relates, according to some embodiments, to compositions and methods for treatment of an abnormal tissue (e.g., cancer). For example, a method may comprise administering to a subject in the region of the abnormal tissue a composition (e.g., a pharmaceutical and/or radiopharmaceutical composition) having a basic pH (e.g., greater than about 9). A radiopharmaceutical composition may comprise, in some embodiments, an admixture of (a) a first radionuclide composition comprising an unsealed, non-colloidal, radioactive, free holmium-166 (166Ho) and/or unsealed, non-colloidal, radioactive, free metal ion of holmium-166 (166Ho) (e.g., 166Ho3+) and (b) a second radionuclide composition comprising an unsealed, non-colloidal, radioactive, free lutetium-177 (177Lu) and/or an unsealed, non-colloidal, radioactive, free metal ion of lutetium-177 (177Lu) (e.g., 177Lu3+).

Abstract: The present invention relates to compositions and methods for preventing migraines. The migraine prophylaxis composition is a single dosage form comprising at least one form of elemental magnesium and at least one NSAID. The prophylaxis composition, comprising at least one form of elemental magnesium and a therapeutically effective concentration of acetylsalicylic acid may also provide cardiac protection and prevent cardiovascular diseases.

Abstract: The invention relates to a tablet capable of being chewed or disintegrated in the oral cavity, which comprises a pharmaceutically active ingredient, and a matrix comprising directly compressible dextrose monohydrate and sucralose, said tablet being substantially fat free and said matrix being substantially free of non-saccharide, water soluble polymeric binders.

Abstract: The present invention deals with a multiparticulate tablet, which disintegrates in the mouth containing: i) a proton pomp inhibiting agent, in particular of the benzimidazole type, in the form of enteric coated microgranules, which enteric coated granules are overcoated with at least one barrier coating, such as for instance a methacrylic copolymer-based protective film; ii) at least one antacid in the form of granules, for instance based on CaCO3 and/or Mg(OH)2 and/or Al(OH)3; and, iii) a mixture of excipients comprising at least one disintegrating agent, one diluent agent, a lubricant, and optionally a swelling agent, a permeabilising agent, sweeteners, flavourings and colours. Furthermore, the present invention is directed to processes for the manufacture of the tablet and its use in the treatment of gastrointestinal disorders.

Abstract: A laxative is provided containing a mixture of prune juice, magnesium, magnesium hydroxide and purified water.

Abstract: The present invention relates to new aminothiazole modulators of beta-3-adrenoreceptor activity, pharmaceutical compositions thereof, and methods of use thereof.

Abstract: Dietary supplement compositions are disclosed. Methods of making and using dietary supplement compositions are also disclosed.

Abstract: The present invention relates to bioactive glass coatings. In particular, the present invention relates to bioactive glass coatings for Ti6Al4V alloys and chrome cobalt alloys, wherein the thermal expansion coefficient of the glass coating is matched to that of the alloy. Such coatings have a particular application in the field of medical prosthetics. The bioactive glass comprises (in mol %) 35-53 SiO2; 2-11 Na20; at least 2% of each of CaO, MgO and K20; 0-15 ZnO; 0-2 B202 and 0-9 P205.

Abstract: The invention relates to formulations of hygroscopic solids with a lipophilic coating layer, and a method of production thereof.

Abstract: A composition and method for the prevention and therapeutic treatment of skin conditions and disorders are disclosed. The composition and method of the invention are particularly directed to the treatment and prevention of dermal irritations. These irritations include, for example, psoriasis, eczema, ichthyosis, pruritus, dryness and dermatitis, which may cause skin to crack, chap or chafe. The composition and method are particularly useful in treating and preventing diaper dermatitis. A therapeutic composition according to the invention includes an agent, which is an enzyme constituent, promoting the synthesis of collagen and the reproduction of cells, particularly skin cells. Such therapeutic agents include, for example, zinc oxide. This agent is generally nonprescription and capable of effectively preventing and treating diaper dermatitis through local or topical application.

Abstract: The present invention relates to new 1-methylpyrazole modulators of substance P release, calcitonin gene-related peptide activity, adrenergic receptor activity, and/or 5-HT receptor activity, pharmaceutical compositions thereof, and methods of use thereof.

Abstract: A method for combating unwanted conditions downstream of the mouth with adhering troches. A method to treat or reduce replication of a virus in throat tissues by releasing an anti-viral from an adhering disc. A method to treat sore throat with time release of Glycyrrhiza extract or collagen from an adhering disc. A method to treat sore throat with topically applied cobalamin. An adhering troche that releases antacid, alginate, bismuth subsalicylate, soluble zinc, such as zinc gluconate, bioactive vitamin B12 (methylcobalamin), antibiotic, or anti-viral. A method to combat bacterial effects downstream of the mouth with topically applied xylitol.

Abstract: This invention relates to chewable tablets containing medicants such as gastrointestinal drugs. More particularly, the invention relates to chewable tablets of medicaments that are sugar free and have reduced calories. Accordingly, the tablets of the invention are suitable for both diabetic and non-diabetic patients.

Abstract: A composition comprising an antacid, and a local, topical anesthetic. The composition is used to relieve pain or discomfort associated with a sore throat, and therefore, the invention is also directed to a method of alleviating the pain or discomfort associated with a sore throat comprising instructing a human to orally administer the composition.

Abstract: A composition and treatment regimen for the amelioration of epidermal herpetic lesions caused by Herpes Simplex Virus (HSV-1) symptoms, Herpes Zoster, and Herpes Genitalia. The treatment includes a regimen of oral administration of a composition including from about 15 to 50 mg of zinc sulfate, from about 5 to 20 mg of magnesium sulfate, from about 15 to 60 mg of thiamin, from about 10 to 30 mg of riboflavin, from about 4 mg to 12 mg of pyridoxine hydrochloride, from about 300 to 1000 mg of ascorbic acid, from about 90 to 300 mg of niacin, and from about 20 to 70 mg of pantothenic acid. The composition and regimen may optionally include an efficacious amount of an amino acid, and preferably about 500 mg of lysine.

Abstract: Systems and methods for use of magnesium hydroxide, either directly or through one or more precursors, doped with a divalent or trivalent metal cation, for removing arsenic from drinking water, including water distribution systems. In one embodiment, magnesium hydroxide, Mg(OH)2 (a strong adsorbent for arsenic) doped with a divalent or trivalent metal cation is used to adsorb arsenic. The complex consisting of arsenic adsorbed on Mg(OH)2 doped with a divalent or trivalent metal cation is subsequently removed from the water by conventional means, including filtration, settling, skimming, vortexing, centrifugation, magnetic separation, or other well-known separation systems. In another embodiment, magnesium oxide, MgO, is employed, which reacts with water to form Mg(OH)2. The resulting Mg(OH)2 doped with a divalent or trivalent metal cation, then adsorbs arsenic, as set forth above. The method can also be used to treat human or animal poisoning with arsenic.

Abstract: An oral pharmaceutical dosage form comprises pharmacologically effective amounts of an acid-susceptible proton pump inhibitor and an H2 receptor antagonist in combination with at least on pharmacologically acceptable excipient which causes a delayed release and/or an extended release of the proton pump inhibitor. The H2 receptor antagonist is included in the dosage form in such a way that it is rapidly released after administration. This dosage form is suitable for the treatment of conditions associated with an excessive secretion of gastric acid and provides a suitable combination of a rapid onset and a long-lasting duration of the effect. The invention also relates to a method for manufacturing such a dosage form and to a method for the treatment of conditions associated with the secretion of gastric acid.

Abstract: The present invention relates to a method and composition for the treatment of skin conditions such as acne. Either natural or artificial sea water is enhanced by the addition of magnesium until it is at least about double the normal natural concentration of magnesium and then used as an application to the skin such as the face for treating acne and improving the appearance of the skin.

Abstract: A composition including a base and a plurality of abrasive particles. An apparatus including a head, and an applicator coupled to the head, the applicator having dimensions suitable for contacting localized areas of human skin. A method including applying a composition to an area of human skin, the composition comprising a base and a plurality of abrasive particles, and manipulating the composition over the area of human skin with a handle-operated instrument.

Abstract: A depilatory kit may comprise a depilatory composition comprising a sulfur-containing depilatory agent and a finishing composition comprising a metal oxide selected from the group consisting of zinc oxide, aluminum oxide, and magnesium oxide. The depilatory composition may further comprise a lactone such as 1,15-cyclopentadecanolide. Methods for using the depilatory kits are also disclosed herein.

Abstract: This invention relates to high surface area materials, such as nanoparticles, that are coated with metal ions. These modified nanoparticles have active sites that bind various gases and/or odorous compounds, thereby removing these compounds from a medium such as air or water. Metal ions are adsorbed onto the surface of the nanoparticle and bound strongly to the surface. By selection of the metal ion, specific gaseous compounds and/or odorous compounds can be targeted and removed efficiently and effectively from both aqueous phase and from the air. The modified nanoparticles are useful in numerous article of manufacture for industrial and consumer use.

Abstract: Buccal aerosol sprays or capsules using polar and non-polar solvent have now been developed which provide biologically active compounds for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, active compound, and optional flavoring agent; formulation II: aqueous polar solvent, active compound, optionally flavoring agent, and propellant; formulation III: non-polar solvent, active compound, and optional flavoring agent; and formulation IV: non-polar solvent, active compound, optional flavoring agent, and propellant.

Abstract: A treatment protocol by which a renal stone patient is administered a chelating agent, generally once a day and preferably by mouth, during a treatment phase and is later administered the same chelating agent once a week, during a “maintenance” phase. The chelating agent is most preferably ethylene diamine tetraacetic acid (EDTA) and may be provided in a dosage form having an enteric coating and at least one external cathode and at least one external anode to create a galvanic current upon contact of the dosage form with the patient's intestinal contents.

Abstract: The present invention relates to compositions that may be swallowable, chewable or dissolvable, comprising various vitamins and minerals, and in a specific embodiment comprising vitamin A, beta carotene, B-complex vitamins, vitamin C, vitamin D3, vitamin E, iron, magnesium and zinc, and methods for using these compositions for nutritional supplementation in subjects undergoing physiologically stressful events, such as, for example and without limitation, pregnancy, lactation or any disease state.

Abstract: The present invention provides a controlled release solid preparation superior in the stability of an active ingredient, which can exhibit pharmacological effects steadily and rapidly after administration, and shows a sustained pharmacological effect for a prolonged period of time: a controlled release solid preparation containing (1) an antacid, (2) an immediate-release part containing a compound unstable to acid and a basic substance, and (3) a sustained-release part containing a compound unstable to acid and a pH-independent material in combination.

Abstract: The present invention relates to compositions and methods for preventing migraines. The migraine prophylaxis composition is a single dosage form comprising at least one form of elemental magnesium and at least one NSAID. The prophylaxis composition, comprising at least one form of elemental magnesium and a therapeutically effective concentration of acetylsalicylic acid may also provide cardiac protection and prevent cardiovascular diseases.

Abstract: The present invention relates to combinations of a proton pump inhibiting agent and at least one buffering agent that have been found to possess improved bioavailability, chemical stability, physical stability, dissolution profiles, disintegration times, as well as other improved pharmacokinetic, pharmacodynamic, chemical and/or physical properties.

Abstract: A vitreous antimicrobial agent that can exhibit excellent antimicrobial properties when added to various types of resins, that has excellent discoloration resistance and hot water resistance, and that can easily be produced at a commercial scale. The vitreous antimicrobial agent includes, relative to 100 mass % of total glass components, 0.1 to 2 mass % of Ag2O, 40.5 to 49 mass % of ZnO, 6 to 9.5 mass % of SiO2, 30.5 to 39.5 mass % of B2O3, 2 to 10 mass % of an alkaline earth metal oxide, and 6 to 7.5 mass % of Na2O; the vitreous antimicrobial agent comprising, in addition to these, 0.01 to 5 mass % of CeO2 as necessary. An antimicrobial resin composition and an antimicrobial product including the vitreous antimicrobial agent.

Abstract: An antiviral agent having been experimentally supported which contains a powder obtained by baking (calcining) dolomite and hydrating a part thereof. Thus, it is possible to provide an antiviral agent which is usable in masks, filters, etc. because of acting directly on viral particles, thus eliminating the infectious capacity of the virus and preventing the invasion of the virus into cells; and a mask and a filter with the use of the antiviral agent.

Abstract: A kit for skin care intended to soften cutaneous signs of ageing, contains in separate packagings, a microdermabrasion composition, a peeling composition, a soothing composition and an anti-ageing composition.

Abstract: The present invention discloses a novel use of magnesium oxide and magnesium hydroxide formulation in adequate proportions and sufficient amounts to induce bowel movement to induce the excretion of HIV, along with HIV-infected pathogens present in the intestinal tract of HIV-infected persons, and to induce the excretion of HIV-loaded bile from said persons. The present invention may prevent the development of drug resistance in HIV patients undergoing drug therapy, may accelerate the recovery of HIV-infected patients, may permit full recovery of these individuals, may prevent viral mutation of patients undergoing HIV drug therapy, and may prevent the onset of AIDS in HIV-infected patients. As an additional benefit, the present invention will contribute to the prevention of adipose tissue disorders, frequently seen in persons undergoing drug therapy. The present invention may be used by itself or together with HAART or other drug therapies.

Abstract: An essentially dry powdered preparation containing a calcium source for the prevention and treatment of calcium deficiency conditions in mammals, e.g. dairy cows, is enclosed in a substantially water soluble, dispersible or disintegrable casing mainly composed of a cellulose material such as e.g. paperboard, cardboard, millboard, or pasteboard, or a gelatinized starch material. The calcium source is preferably a mixture of calcium chloride and calcium propionate enclosed in a cylindrical paperboard or cardboard tube or a gelatinized starch shell closed at both ends, which is administered to an animal with a bolus or bullet gun. The administration is safe and clean and the powdered mixture is quickly released in the stomach or rumen without causing erosion, irritation or inflammation of the mucosa.

Abstract: The present invention relates to a composition and method for the simultaneous alleviation of the symptoms form both acute and chronic gastric and esophageal reflux disorder. The composition of the present invention comprises at least calcium carbonate, aluminum hydroxide, or magnesium hydroxide and limonene, wherein the metal salts treat the acute case of the aforementioned disorder and the limonene is used to treat the chronic case.

Abstract: The present invention is a composition delivering effective amounts of Chasteberry Extract, Pyridoxine, and Magnesium in a single dosage unit and a method of treating PMS and related disorders with the composition.

Abstract: The invention relates to a medical device comprising non-sintered bioactive glass particles or fibres having a diameter in the range 5-100 ?m, bioactive glass comprising SiO2, Na2O, CaO, K2O, MgO, B2O3 and P2O5, wherein the amount of SiO2 is 50-65 wt-% of the final total weight, Na2O is 5-26 wt-% of the final total weight, CaO is 10-25 wt-% of the final total weight, K2O is 0-15 wt-% of the final total weight, MgO is 0-6 wt-% of the final total weight, B2O3 is 0-4 wt-% of the final total weight, and P2O5 is 0-4 wt-% of the final total weight, provided that the total amount of Na2O and K2O is 10-30 wt-% of the final total weight The device is essentially drug free. The invention also relates to the use of said composition for treating lesions associated with compromised or poor vascularisation and for preventing avascular fibrosis.

Abstract: The present disclosure describes a novel composition for the treatment and/or prevention of neurogenic inflammation. Such composition is also useful in the treatment and/or prevention of disease states and conditions associated with neurogenic inflammation. Such disease states and conditions include, but are not limited to, migraine headache, arthritis and fibromyalgia. The composition comprises nutrient compounds in a novel combination and formulation to treat and/or prevent neurogenic inflammation and disease states and conditions associated therewith. By reducing neurogenic inflammation, the compositions of the present disclosure reduce the symptoms associated with neurogenic inflammation, such as pain and systemic inflammation in general.

Abstract: Treatment with magnesium produces a inhibition of acute stent thrombosis under high-shear flow conditions without any hemostatic or significant hemodynamic complications.

Abstract: Benzodiazepine withdrawal induced anxiety is treated by administration of an enkephalinase inhibitor, and a gamma-aminobutyric acid (“GABA”) precursor, or an endorphin or enkephalin releaser. These components promote restoration of normal neurotransmitter function and are non-addictive. Use of the enkephalinase inhibitor D-phenylalanine, the GABA precursor glutamine, the serotonin precursor 5-HTP, glycine, and taurine, in combination with coenzymatic functionality of folic acid is preferred for activation of ligand-gated Cl? channel in the central nervous system. Food supplement embodiments provide the human body nutritional supplements to intake certain neurotransmitter precursor substrates, thereby enabling patients of all ages to self-regulate their ability to quell perturbations to equilibrium and simultaneously to adverse effects upon normal physiological and psychological functioning attributable to induced anxiety and panic associated with benzodiazepine withdrawal.

Abstract: A composition and method for the prevention and therapeutic treatment of skin conditions and disorders are disclosed. The composition and method of the invention are particularly directed to the treatment and prevention of dermal irritations. These irritations include, for example, psoriasis, eczema, ichthyosis, pruritus, dryness and dermatitis, which may cause skin to crack, chap or chafe. The composition and method are particularly useful in treating and preventing diaper dermatitis. A therapeutic composition according to the invention includes an agent, which is an enzyme constituent, promoting the synthesis of collagen and the reproduction of cells, particularly skin cells. Such therapeutic agents include, for example, zinc oxide. This agent is generally nonprescription and capable of effectively preventing and treating diaper dermatitis through local or topical application.

Abstract: The present invention relates to a powder mixture for resorbable calcium phosphate biocements, which mixture consists of 40–99% by volume of powder having a particle size of 0.1–10 ?m, 1–20% by volume of powder having a particle size of 10–43 ?m and 0–59% by volume of powder having a particle size of 43–315 ?m, which powder is obtained by grinding the spontaneously crystallizing melts of a material comprising crystalline and X-ray amorphous phases, which material a) according to 31P-NMR measurements, contains Q0-groups of orthophosphate and Q1-groups of diphosphate, the orthophosphates or Q0-groups making up 65 to 99.9% by weight relative to the total phosphorus content of the powder mixture and the diphosphates or Q1-groups making up 0.1 to 35% by weight relative to the total phosphorus content of the powder mixture, and b) according to X-ray diffractometric measurements and relative to the total weight of the powder mixture, contains 35 to 99.

Abstract: A method of reducing inflammation in a variety of disorders by using an intraperitoneal solution of magnesium. The solution can be used for treating inflammatory and inflammation-related disorders in animals and/or humans. Application of the solution reduces inflammation and thereby assists in the healing process. An alternative method involves the intraperitoneal administration of a solution containing magnesium salts. Another alternative method provides for treatment of inflammatory and inflammation-related disorders in animals by way of intraperitoneal administration of a solution containing magnesium salts, methenamine or its salts and dextrose. The method further provides the use of methenamine or its salts and/or dextrose in combination with magnesium.

Abstract: It discloses a facial treatment mask that can be applied directly on the user's skin, with improved organoleptic properties, along with a process for preparing the product that serves as a base for the mask. Said product consists of the mixture of two separate phases, immediately prior to application. Each phase consists of a series of ingredients which give them their appearance of a suspension and gel respectively, so that when combined together, they form a genuine emulsion. The process for preparing each phase includes various steps of mixing and combining their respective ingredients, with the help of blending and kneading devices that operate for pre-determined periods of time. The application is conducted within a maximum period of approximately 4 to 5 minutes, and the polymerisation or setting is achieved within a minimum time frame of approximately 15 minutes.

Abstract: A composition that will substantially reduce the deleterious effects of alcohol on the body and substantially reduce the side effects associated with hangovers (i.e. headaches, dizziness, nausea, dry mouth, etc) when taken as recommended. The composition includes an effective amount of (I)-glycine, (I)-glutathione, thiamine, magnesium, selenium, molybdenum. Other vitamins, mineral compounds, flavoring, coloring, and solubility agents may also be added.

Abstract: A dietary supplement for benefitting human bone health includes a calcium source, a source of vitamin D activity, and an osteoblast stimulant. A preferred calcium source is microcrystalline hydroxyapatite, which also contains protein (mostly collagen), phosphorus, fat, and other minerals. A preferred source of vitamin D activity is cholecalciferol, and a preferred osteoblast stimulant is ipriflavone. In addition to these basic ingredients, the composition can further include various other minerals known to occur in bone, vitamin C, and glucosamine sulfate, all of which exert beneficial effects on growth and maintenance of healthy bone. A method for benefitting human bone health involves administering a daily regimen of the dietary supplement.

Abstract: A body pigment with a good skin feel for cosmetics is provided which has an appropriate crumbling property and combines slipping property and adhesiveness without compromising oil absorption. The body pigment is comprised of a metal-containing compound and has a structure in which leaf-shaped flakes are combined and/or intersected.

Abstract: A highly acidic metalated organic acid composition and its preparation. The acidic composition can be prepared by mixing a monovalent or polyvalent cation and an organic acid in the presence of a strong oxyacid, wherein the resultant acidic composition is less corrosive to a ferrous metal than a solution of a mineral acid having the same acidic pH value as that of the acidic composition, and where in the acid composition is more biocidal than a mixture of the organic acid and a metal salt of the organic acid which mixture has the same acid normality value as that of the acidic composition. The acidic composition can be prepared by mixing at least one regenerating acid, at least one metal base, and at least one organic acid, wherein the amount of the regenerating acid is in excess of the equivalent amount of the metal base.